Matribhumi Samachar English
US Food and Drug Administration (FDA) has accepted the company’s Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania–(Newsfile Corp. – August 21, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing …
Read More »Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania–(Newsfile Corp. – August 4, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus“) and Helix Nanotechnologies Inc. (“HelixNano“), a Boston-based biotech company focused on developing an advanced mRNA platform …
Read More »